表紙
市場調查報告書

創新的醫藥品:藥價設定、償付形勢製圖(2020年)

Innovative Drugs: Mapping the Pricing and Reimbursement Landscape

出版商 FirstWord 商品編碼 940414
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
創新的醫藥品:藥價設定、償付形勢製圖(2020年) Innovative Drugs: Mapping the Pricing and Reimbursement Landscape
出版日期: 2020年02月02日內容資訊: 英文
簡介

由於藥物的創新,大幅度改善患者的治療結果,有時會提供治療該疾病的非常有效的藥物。從2018年1月到2019年6月在美國已批准的55種醫藥品中,只有少數在美國以外的主要市場發售。美國以外的市場上創新的醫藥品的競爭情形,HTA (Health Technology Assessments),由於長期的價格談判,或是小規模開發商的資源不足等要素形成。

本報告提供創新的醫藥品的藥價設定、償付環境調查,主要醫藥品概要,核準情況,HTA、市場投入狀況,銷售額狀況等個別彙整。

摘要整理

調查手法、調查目的

概要

  • 認證核可藥
  • 銷售資料
  • P&R / HTA活動

藥物情形報告

抗感染藥

  • Baloxavir Marboxil
  • Delafloxacin
  • Doravirine
  • Eravacycline Dihydrochloride
  • Ibalizumab
  • Omadacycline tosylate
  • Tecovirimat
    • 產品概要
    • 核准
    • HTA、市場投入
    • 銷售額等

心血管

  • 血管收縮素II
  • Tafamidis meglumine
    • 產品概要
    • 核准
    • HTA、市場投入
    • 銷售額等

皮膚科

  • 鹽酸西環黴素
    • 產品概要
    • 核准
    • HTA、市場投入
    • 銷售額等

腸胃

  • Naldemedine
  • Prucalopride succinate
  • Telotristat ethyl
    • 產品概要
    • 核准
    • HTA、市場投入
    • 銷售額等

血液製劑

  • Avatrombopag
  • Caplacizumab
  • Fostamatinib
  • Lusutrombopag
  • Ravulizumab
  • Sodium zirconium cyclosilicate
    • 產品概要
    • 核准
    • HTA、市場投入
    • 銷售額等

免疫系

  • Elapegademase
  • Emapalumab
    • 產品概要
    • 核准
    • HTA、市場投入
    • 銷售額等

發炎性疾病

  • Risankizumab
  • Tildrakizumab
    • 產品概要
    • 核准
    • HTA、市場投入
    • 銷售額等

代謝障礙

  • Pegvaliase
  • Semaglutide
  • Vestronidase-alfa
    • 產品概要
    • 核准
    • HTA、市場投入
    • 銷售額等

神經科學

  • 大麻二酚
  • Edaravone
  • Fremanezumab
  • Galcanezumab
  • Siponimod fumaric acid
  • Solriamfetol
  • Stiripentol
    • 產品概要
    • 核准
    • HTA、市場投入
    • 銷售額等

腫瘤

  • Alpelisib
  • Apalutamide
  • Calaspargase Pegol
  • Cemiplimab
  • Darolutamide
  • Duvelisib
  • Erdafitinib
  • Gilteritinib Fumarate
  • Glasdegib Maleate
  • Ivosidenib
  • Larotrectinib
  • Lorlatinib
  • Midostaurin
  • Mogamulizumab
  • Moxetumomab pasudotox
  • Neratinib
  • Polatuzumab vedotin
  • Rucaparib
  • Selinexor
  • Tagraxofusp
  • Talazoparib
    • 產品概要
    • 核准
    • HTA、市場投入
    • 銷售額等

眼科

  • Cenegermin
  • Latanoprostene bunod
  • Netarsudil dimesylate
  • Latanoprost; Netarsudil Dimesylate
    • 產品概要
    • 核准
    • HTA、市場投入
    • 銷售額等

罕見疾病

  • Amifampridine Phosphate
  • Inotersen
  • Lanadelumab
  • Migalastat
  • Nusinersen
  • Patisiran sodium
    • 產品概要
    • 核准
    • HTA、市場投入
    • 銷售額等

呼吸系統

  • Mepolizumab
    • 產品概要
    • 核准
    • HTA、市場投入
    • 銷售額等

女性的疾病

  • Brexanolone
  • Elagolix Sodium
  • Romosozumab
    • 產品概要
    • 核准
    • HTA、市場投入
    • 銷售額等
目錄
Product Code: 596201553

Drug innovation is delivering highly-effective medicines that significantly improve patient outcomes and, in some cases, are curative of disease. Yet of the 55 medicines that were approved in the US between January 2018 and June 2019, only a handful have been launched in a major market outside the US. Health Technology Assessments (HTA), protracted price negotiations or the fact that smaller developers do not have the resources to overcome challenging market access obstacles are all shaping the competitive landscape for innovative drugs in non-US markets.

Which companies are involved? What products have made the grade and where? When could new competitive threats emerge? For answers turn to the fully-updated and expanded ‘Innovative Drugs: Mapping the Pricing and Reimbursement Landscape’. Comprising a detailed report and usable data set in MS Excel™, this comprehensive and granular analysis exposes-at a product level-the pricing, reimbursement and HTA status of innovative drugs in leading non-US markets.

Key facts about this report

1) The Analysis Report focuses on the latest developments

Executive Summary

A review of the issues and challenges that are impacting product launch.

Overview

Summary information of drugs approved by therapy area and company, and sales data for innovative products that have been launched.

Pricing, reimbursement and HTA activity by country

  • Canada: Patented Medicine Price Review Board;
  • France: Haute Autorité de Santé;
  • Germany: Gemeinsame Bundesausschuss/Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesenis;
  • UK: National Institute for Health and Care Excellence.

Product level HTA status analysis

  • Product overview;
  • Regulatory approvals;
  • HTA status by country/region.

Products covered in the Analysis Report

The report covers 68 products across a range of therapy areas and conditions including: apalutamide, caplacizumab, delafloxacin, elagolix sodium, fremanezumab, ibalizumab, migalastat, mogamulizumab, risankizumab, rucaparib and semaglutide.

2) The Data Set gives the long view

The Excel Data Set provides a wider perspective and covers 140 products approved in the US and/or the EU between January 2016 and June 2019.

  • Products: Product level analysis covers products from Tymlos (abaloparatide; Radius Health), Verzenio/Verzenios (abemaciclib; Eli Lilly) and Calquence (acalabrutinib; AstraZeneca) to Ingrezza (valbenazine; Neurocrine) and Venclexta/Vencyxto (venetoclax; AbbVie/Genentech) and Mepsivii (vestronidase-alfa; Ultragenyx).
  • Therapy areas: The 140 products cover over 15 therapy areas-from leading areas such as oncology, anti-infectives and respiratory to rare diseases, gastrointestinal and neurological disorders.
  • Conditions: 108 conditions are covered including cancer (various), asthma, dry eye, DMD, Hepatitis C, IBS, psoriasis, Parkinson's disease, epilepsy and diabetes.
  • Companies: The products of leading pharmaceutical and biologics companies including AbbVie, Ablynx NV and Acadia Pharmaceuticals to Ultragenyx, Valeant and Vertex Pharmaceuticals.
  • Markets: The HTA status, regulatory approvals and sales data in Australia, Canada, France, Germany and the UK.

This report will enable you to...

  • Review the pricing, reimbursement and HTA status of each product at the national level
  • Profile the therapy areas that are being targeted
  • Estimate likely regulatory approval decisions using average timeframes
  • Identify products that have been approved but yet not referred for HTA assessment
  • Assess the impact of biologic players in the innovative drug space
  • Identify innovative products that have only been launched in the US
  • Profile innovative therapies in key therapy areas and acute/chronic conditions

What to expect

This report delivers two class-beating analysis resources

1. Analysis Report

An Analysis Report, rich in charts and tables, this detailed analytical report provides clear insights into 68 products approved or reviewed between January 2018 and June 2019.

2. Data Set

Delivered in Microsoft Excel, the Data Set includes all the data on 140 products assessed between January 2016 and June 2019, which can be used for further analysis or incorporated into internal decision support systems.

Why choose FirstWord?

Are you fed up with management reports packed out with uncorroborated content? If this is your experience, then turn to FirstWord because...

  • All our information is derived from detailed research
  • We deliver hard, verified facts and statistics and don't pack our reports with spurious observations
  • Our reports are based on latest research-we don't reuse or recycle content
  • We have the expertise to create on-target content that dives deeply into the pressing commercial and market access issues of the day

Table of Contents

Executive summary

Research methodology and objectives

Overview

  • Approved drugs
    • By therapy area
    • By route of administration
    • By company
  • Sales Data
  • P&R/HTA Activity
    • Canada
    • France
    • Germany
    • UK

Drug status reports

Anti-Infectives

  • Baloxavir Marboxil
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Delafloxacin
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Europe
    • Sales
  • Doravirine
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Eravacycline Dihydrochloride
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Ibalizumab
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Omadacycline tosylate
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Tecovirimat
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales

Cardiovascular

  • Angiotensin II
    • Key updates:
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Tafamidis meglumine
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales

Dermatology

  • Sarecycline hydrochloride
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales

Gastrointestinal

  • Naldemedine
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Prucalopride succinate
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Telotristat ethyl
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales

Haematology

  • Avatrombopag
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Caplacizumab
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Fostamatinib
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Europe
    • Sales
  • Lusutrombopag
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Ravulizumab
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Sodium zirconium cyclosilicate
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales

Immunology

  • Elapegademase
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Emapalumab
    • Product overview
    • Regulatory approvals
    • HTA and market launch

Inflammatory disorders

  • Risankizumab
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Tildrakizumab
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch

Metabolic Disorders

  • Pegvaliase
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Semaglutide
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Vestronidase-alfa
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales

Neuroscience

  • Cannabidiol
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Europe
    • Sales
  • Edaravone
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Fremanezumab
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Galcanezumab
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Siponimod fumaric acid
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Solriamfetol
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Stiripentol
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales

Oncology

  • Alpelisib
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Apalutamide
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Calaspargase Pegol
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Cemiplimab
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Darolutamide
    • Regulatory approvals
    • HTA and market launch
  • Duvelisib
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Erdafitinib
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Gilteritinib Fumarate
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Glasdegib Maleate
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Ivosidenib
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Larotrectinib
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Lorlatinib
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Midostaurin
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Mogamulizumab
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Moxetumomab pasudotox
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Neratinib
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Polatuzumab vedotin
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Rucaparib
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Selinexor
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Tagraxofusp
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Talazoparib
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales

Ophthalmology

  • Cenegermin
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Latanoprostene bunod
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Netarsudil dimesylate
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Latanoprost; Netarsudil Dimesylate
    • Product overview
    • Regulatory approvals
    • HTA and market launch

Rare diseases

  • Amifampridine Phosphate
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Inotersen
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Lanadelumab
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Migalastat
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Nusinersen
    • Key updates
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales
  • Patisiran sodium
    • Product overview
    • Regulatory approvals
    • HTA and market launch
    • Sales

Respiratory

  • Mepolizumab
    • Product overview
    • Regulatory approvals
    • HTA and market launch

Women's health

  • Brexanolone
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Elagolix Sodium
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Romosozumab
    • Product overview
    • Regulatory approvals
    • HTA and market launch
  • Sales